Better vaccines, immune response with new additives

OHSU awarded $2.1 million to develop new adjuvants for Zika, Chikungunya viruses

By Franny White October 30, 2019 Portland, Oregon

Downloads

Jay Nelson, Ph.D., founder and director of the OHSU Vaccine and Gene Therapy Institute, senior scientist at the Oregon National Primate Research Center, and professor of molecular microbiology and immunology in the OHSU School of Medicine. (OHSU)

Victor DeFilippis, Ph.D.

Victor DeFilippis, Ph.D., looks at a blot from his research on adjuvants, vaccine additives that help people have stronger immune responses against a virus. (OHSU/Kristyna Wentz-Graff)

OHSU/Kristyna Wentz-Graff

Adjuvant research

Victor DeFilippis, Ph.D., (left) talks with a colleague in the lab, October 8, 2019. (OHSU/Kristyna Wentz-Graff)